THE WOODLANDS, Texas,
June 14, 2014 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the
74th Scientific Sessions of the American Diabetes
Association (ADA) in San Francisco
on LX4211, an oral, first-in-class, dual inhibitor of sodium
glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to
lower blood glucose levels through two insulin-independent
mechanisms of action. Results presented from a clinical study
showed that LX4211 significantly reduced postprandial glucose
levels in type 2 diabetes patients with moderate to severe renal
impairment.
In a double-blind, randomized, placebo-controlled,
parallel-group study with 31 patients, LX4211 provided
statistically significant reductions (p=0.003) in postprandial
glucose in type 2 diabetes patients with moderate to severe renal
impairment. In a sub-group analysis of patients with the most
advanced renal impairment, defined as those with a glomerular
filtration rate (GFR) of less than 45 ml/min/1.73 m2,
LX4211 similarly reduced postprandial glucose as compared to
placebo (p=0.002). Exhibiting its inhibition of SGLT1, LX4211
produced significant elevations in both total GLP-1 (p=0.017) and
active GLP-1 (p=0.042) across all patients. There were no
serious adverse events and no discontinuations due to adverse
events during the study.
In an additional presentation at ADA, Lexicon presented data
showing that LX4211 improved glycemic control in mice with poorly
controlled type 1 diabetes. LX4211 significantly lowered
blood glucose levels in both the low dose (2 mg/kg LX4211) and high
dose (30 mg/kg LX4211) groups while reducing the occurrences of
hypoglycemia. In addition, LX4211 significantly slowed the
rise in HbA1c levels as compared to vehicle-treated mice with
poorly controlled type 1 diabetes.
Complete presentations of the data are available for download
from Lexicon's corporate website www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company
focused on developing breakthrough treatments for human
disease. Lexicon currently has drug programs in clinical
development for diabetes, carcinoid syndrome, and other
indications, all of which were discovered by Lexicon's research
team. Lexicon has used its proprietary gene knockout
technology to identify more than 100 promising drug targets.
For additional information about Lexicon and its programs, please
visit www.lexpharma.com.
Safe Harbor Statement
This press release contains
"forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2013, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.